Is Clovis Oncology Really a Buyout Candidate?

If enough people think something, does that make it true?

That's the question investors should ask themselves when it comes to Clovis Oncology (NASDAQ: CLVS), which saw its stock skyrocket 371% in November. The reason: The return of merger and acquisition (M&A) activity in the pharma industry has renewed hope that the company might be an attractive buyout candidate.